News · 26 weeks72+56%
2026-03-012026-08-23
Mix3890d
- SEC Filings23(61%)
- Other11(29%)
- Analyst3(8%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew and Imperial College London launch centre to accelerate innovation in surgical roboticsMarking a new approach to innovation in medical robotics, the new centre will bring advances from a leading surgical robotics research group to patients more quickly Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, and Imperial College London have launched a five-year partnership to deliver breakthrough research and innovation for robotic surgery for musculoskeletal conditions. The first-in-kind partnership will bring together a globally renowned academic laboratory with engineers from Smith+Nephew to accelerate the translation of academic breakthroughs in fields such as computer vision and sensing into advanced techniques in robotic surgery. The techniques will
- PRSmith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle optionsSmith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces a breakthrough in RF resection technology for hip with its new FLOW FLEXTEND COBLATION Wand. Designed as an extension of its proprietary FLOW~IQ◊ technology with an adjustable-angle tip, the FLOW FLEXTEND Wand is designed to give surgeons enhanced joint access1* and precise tissue targeting3 for hard-to-reach hip, knee and shoulder anatomies. Determining the root cause of a patient’s hip pain can be very challenging and repairs are procedurally complex. Current wand offerings - such as knee wands that have simply been made longer – fall short of surgeons’ needs for an improved option to better access al
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- ANALYSTSmith & Nephew downgraded by AnalystAnalyst downgraded Smith & Nephew from Overweight to Neutral
- PRSmith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement WeekCanton, Ohio—As thousands of football fans descend on Canton for the 2026 Pro Football Hall of Fame Enshrinement Week, Smith+Nephew, the Global medical technology company, will join the celebration with a series of engagement activities highlighting the connection between movement, recovery and the enduring spirit of the game. Smith+Nephew is the official Joint Replacement and Sports Medicine Technology Partner of the Pro Football Hall of Fame. Throughout the Hall of Fame Enshrinement Week and Fan Fest, Smith+Nephew will welcome visitors to its interactive booth, which will feature special appearances by Pro Football Hall of Famers, live podcast programming, and a giveaway of an official he
- ANALYSTSmith & Nephew downgraded by BarclaysBarclays downgraded Smith & Nephew from Equal Weight to Underweight
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovationSmith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been granted De Novo classification by the U.S. Food & Drug Administration (FDA) for its TESSA Spatial Surgery System. Utilizing cutting-edge accelerated computing and AI technology, the TESSA (Tracking Enabled Spatial Surgery Assistant) System brings personalized planning, augmented reality, advanced imaging, navigation, and real-time tracking to help transform arthroscopic procedures, leveraging technology originally developed by Perceive3D S.A., a spin-off from the University of Coimbra that became part of Smith+Nephew through acquisition. The TESSA System uses preoperative MR or CT scans with
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based careSmith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, today announced ASC Solutions: an expanded enterprise strategy for ambulatory surgery centers (ASCs) that takes a customer-centric approach to helping ASC customers realise their key objectives of cost optimization, quality, and outcome performance. ASC Solutions helps customers to source best-in-class expertise, differentiated procedural technologies and advanced data and analytics to help ASCs accelerate growth, improve operational performance, and drive patient outcomes within an increasingly complex and value-based care environment. "ASC Solutions enables our customers to leverage Smith+Nephew’s strategic allia
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew introduces groundbreaking LYNX™ COBLATION™ Laryngeal Wand for ENT surgeonsDelivering versatility for airway procedures in a single, streamlined surgical solution Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the commercial launch of its LYNX COBLATION Laryngeal Wand, a multi-purpose solution designed by laryngologists for laryngology. Backed by surgeon insights and the need for versatility, the LYNX Wand is designed with a long working length and also fine dissection and mass debulking capabilities to support procedures from supraglottis to trachea1,2 at low temperatures*3 with reduced risk of airway fire.†4-6 The LYNX COBLATION Laryngeal Wand advances airway procedural solutions thanks to several key differentiators,
- PRNew German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisionsSmith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany. Published in internationally recognised journal of surgery Die Chirurgie, the new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system. New consensus provides practical framework for post-surgical careThis new interdisciplinary consensus is the first in Germany to translate
- PRNew German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complicationsSmith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany and has been published in the internationally recognised journal of surgery Die Chirurgie. The new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system. New guidelines link prevention strategies to improved health economics A recently published interdisciplinary expert consensus s
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
SNN FAQ
7 questionsWhat does Smith & Nephew SNATS Inc. do?
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as...Where does SNN stock trade?
Smith & Nephew SNATS Inc. (SNN) is listed on NYSE.What sector and industry is SNN in?
Smith & Nephew SNATS Inc. operates in the Health Care sector, Industrial Specialties industry.Does SNN pay a dividend?
Yes. SNN's next ex-dividend date is 2026-10-02 with a declared cash dividend of $0.30 per share, payable 2026-11-06.What are analysts saying about SNN?
Smith & Nephew SNATS Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Neutral on 2026-08-06. Recent price targets cluster around $3750.00.What companies are similar to SNN?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare SNN side-by-side with any of them on Quantisnow.How can I track SNN on Quantisnow?
Quantisnow aggregates Smith & Nephew SNATS Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNN to receive live email and push alerts on every new disclosure.